CDH13

Across TCGA pan-cancer cohorts, CDH13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDH13 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CDH13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDH13 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where CDH13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.838	0.565	.005	17	view →
CCRCC	DFS	Tertile	III,IV	0.732	0.375	.006	11	view →
LUAD	DFS	Median	All	0.888	0.944	.019	4	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDH13–GBM (DFS)

Open the GBM breakdown →